Klinisk validering av secretoneurin biomarkør test

Offentlig prosjektsammendrag

CardiNor AS is a Norwegian biotech company established in June 2015 to develop and commercialise assays for secretoneurin (SN), an important new biomarker for cardiovascular and kidney disease (CVD). Patents have been granted in the US and Europe. In addition to our CE marked SN ELISA we have developed with the support of NFR, IPN project number 327882 widen SN, a bead-based assay for high throughput platforms that can easily be adopted on the immunoassay platform of the major IVD companies like Roche, Abbot, Siemens etc. We know that SN predicts death (100% certain) and we now see support for SN finding patients who may be relevant for treatment for problems with cardio-renal axis= SGLT2-I, GLP1-RA or specific aldosterone inhibitors (Finerenone). The aim of this project is to expand the clinical use of our products by conducting numerous clinician trials of patients with cardiovascular and kidney disease.